Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes

Clinical Chemistry

Volumn 51, Issue 5, 2005, Pages 891-897

  Herrmann, Wolfgang ^a   Schorr, Heike ^a   Obeid, Rima ^a   Makowski, Julia ^a   Fowler, Brian ^b   Kuhlmann, Martin K ^a,c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c RENAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; CYSTATHIONINE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHYLMALONIC ACID; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; VITAMIN B GROUP;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RISK FACTOR; THROMBOSIS; VITAMIN BLOOD LEVEL;

AGED; CYSTATHIONINE; CYSTEINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METHIONINE; METHYLMALONIC ACID; MIDDLE AGED; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE; TRANSCOBALAMINS; VITAMIN B 12; VITAMIN B 6;

EID: 17744374782     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.044453     Document Type: Article

References (44)

1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2002;356:147-52.
2. Obeid R, Kuhlmann M, Köhler H, Herrmann W. Response of homocysteine and related metabolites to vitamin treatment in hyperhomocysteinemic dialysis patients. Clin Chem 2005;51: 196-201.
3. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138-41.
4. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
5. Becker A, Henry RM, Kostense PJ, Jakobs C, Teerlink T, Zweegman S. et al. Plasma homocysteine and S-adenosylmethionine in erythrocytes as determinants of carotid intima-media thickness: different effects in diabetic and non-diabetic individuals. The Hoorn Study. Atherosclerosis 2003;169:323-30.
6. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004;140:94-100.
7. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12:2181-9.
8. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55: 1028-35.
9. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985;31:624-8.
10. Garibotto G, Sofia A, Saffioti S, Russo R, Deferrari G, Rossi D, et al. Interorgan exchange of aminothiols in humans. Am J Physiol Endocrinol Metab 2003;284:E757-6.
11. Li N, Chen YF, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002;39: 443-8.
12. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002;106:1275-81.
13. 6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. Eur J Clin Invest 2003;33:209-15.
14. Loehrer FM, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S-adenosylmethionine:S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998;13:656-61.
15. Perna AF, Ingrosso D, Castaldo P, Galletti P, De Santo NG. Homocysteine and transmethylations in uremia. Kidney Int Suppl 2001;78:3230-3.
16. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, et al. S-Adenosylmethionine and methylation. FASEB J 1996; 10:471-80.
17. Schatz RA, Wilens TE, Sellinger OZ. Decreased in vivo protein and phospholipid methylation after in vivo elevation of brain S-adenosyl- homocysteine. Biochem Biophys Res Commun 1981;98: 1097-107.
18. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
19. Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999;9:49-54.
20. McKeever M, Molloy A, Weir DG, Young PB, Kennedy DG, Kennedy S, et al. An abnormal methylation ratio induces hypomethylation in vitro in the brain of pig and man, but not in rat. Clin Sci (Lond) 1995;88:73-9.
21. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-9.
22. 12 and folate. Res Exp Med (Berl) 2001;200:155-68.
23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. http://www.kidney.org/professionals/kdoqi/guidelines_ ckd/toc.htm (accessed May 19, 2004).
24. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404-13.
25. Ulleland M, Eilertsen I, Quadros EV, Rothenberg SP, Fedosov SN, Sundrehagen E, et al. Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum. Clin Chem 2002; 48:526-32.
26. Poirier LA, Brown AT, Fink LM, Wise CK, Randolph CJ, Delongchamp RR, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 2001; 50:1014-8.
27. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001;39:739-46.
28. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo. Circ Res 1999;84:409-16.
29. Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272:25380-5.
30. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular, smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
31. Tsai MY, Aras O, Sozen H, Hanson NQ, Woll PS, Arenas VL, et al. Plasma homocysteine levels in living kidney donors before and after uninephrectomy. J Lab Clin Med 2004;143:340-3.
32. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl 2001;78:S234-7.
33. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
34. van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999;56:1064-71.
35. 12 in patients with chronic renal failure. Nephron Clin Pract 2005;99:c42-8.
36. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homoeysteine between competing pathways. J Biol Chem 1984;259:9508-13.
37. Carmel R. Measuring and interpreting holo-transcobalamin (holotranscobalamin II). Clin Chem 2002;48:407-9.
38. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999;48: 631-5.
39. Fu W, Dudman NP, Perry MA, Young K, Wang XL. Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine. Biochem Biophys Res Commun 2000;271:47-53.
40. Guerra-Shinohara EM, Morita OE, Pagliusi RA, Blaia-D'Avila VL, Allen RH, Stabler SP. Elevation of serum Sadenosylhomocysteine in severe cobalamin deficient megaloblastic anemia. Blood 2001; 98:13a.
41. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D. D-Aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 1997;8:95-104.
42. 6 concentrations. Eur J Clin Invest 2003;33:17-25.
43. Stabler S, Allen RH. Quantification of serum and urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. Clin Chem 2004;50:365-72.
44. Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20.